IgE-mediated Allergy to Pembrolizumab and Successful Desensitization

J Investig Allergol Clin Immunol. 2023 Jul 27;33(4):304-306. doi: 10.18176/jiaci.0858. Epub 2022 Sep 5.

Authors

I Torrado¹, M I Peña^{1

2}, A Tsopana¹, I Mendoza³, J M Beitia^{1

2}, B Mateo^{1

2}, L E Chara⁴, A Vega^{1

2}

Affiliations

¹ Allergy Department, University Hospital of Guadalajara, Spain.
² ARADyAL Spanish Thematic Network and Co-operative Research Centre RD16/0006/0023, ISCIII, Madrid, Spain.
³ Pharmacy Department, University Hospital of Guadalajara, Spain.
⁴ Oncology Department, University Hospital of Guadalajara, Spain.

PMID: 36059234
DOI: 10.18176/jiaci.0858

No abstract available

Keywords: Allergy; Anti-PD-1 antibody; Desensitization; Lung cancer; Pembrolizumab.

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Desensitization, Immunologic
Humans
Hypersensitivity*
Immunoglobulin E

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized
Immunoglobulin E